Advanced Filters
noise

Minatoga, Japan Clinical Trials

A listing of Minatoga, Japan clinical trials actively recruiting patients volunteers.

Found 65,447 clinical trials

Safety and Efficacy of Xalkori ROS1

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

18 years of age All Phase N/A
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Individual Variations of Taste and Smell Perception in Alcohol Use Disorder (AUD)

Background Alcohol use disorder (AUD) is the most common substance use disorder in the world. Long-term AUD can affect a person s sense of taste and smell. This natural history study will compare alcohol drinking behaviors and measures of taste and smell in people with and without AUD. Objective To …

18 - 65 years of age All Phase N/A
N Ni Qihong, M.D.

Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis

The study aims to compare the modified approach through ipsilateral deep calf venous access of contralateral femoral venous access with the traditional approach through ipsilateral popliteal venous access for mixed type deep venous thrombosis (DVT), and determine whether it can achieve similar therapeutic effects as central type DVT.

18 - 85 years of age All Phase N/A
M Muserref KELES, PhD

Validity and Reliability of a Turkish Version of MD Anderson Inventory Dysphagia Inventory

The purpose of this study is to M.D. Validity of the Turkish version of the Anderson Dysphagia Inventory for the Turkish population, reliability, and cultural adaptation.

18 - 85 years of age All Phase N/A

Effectiveness of Multisystemic Therapy for Adolescents From Families With Intellectual Disabilities

The goal of this observational study is to determine the effectiveness of a specialisation of multisystemic therapy (MST) for adolescents with severe behavioural problems from families with an intellectual disability (ID; MST-ID). To achieve this goal, a mixed method study design is used. To this end, a quantitative and a …

10 - 19 years of age All Phase N/A
H Hande Gül Ulusoy Gezer, MSc

Weight Loss and CLOCK 3111T/C Polymorphism

The goal of this observational study is to investigate the relationship of CLOCK 3111T/C (rs1801260) gene variant with nutritional habits, nutritional status, chronotype, sleep quality, some biochemical parameters in overweight or obese individuals and to observe its effect on weight loss diet intervention. The main questions it aims to answer …

20 - 50 years of age All Phase N/A
R Rachael Coleman, MPH

Obesity and Pediatric Multiple Sclerosis

Obesity is one possible contributor to severity of multiple sclerosis and progression of the disease. We already know that obesity is a risk determinant for acquiring MS, yet the impact of obesity on pediatric MS disease expression and course is unknown. This study will evaluate the relationship between obesity, obesity-derived …

10 - 20 years of age All Phase N/A

Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome

This study investigates a type of cell, called abnormal clonogenic epithelial cells, in patients with bronchiolitis obliterans syndrome who have had an donor stem cell transplant or a lung transplant. Learning more about clonogenic cells in these patients may help doctors to detect signs of bronchiolitis obliterans syndrome earlier in …

years of age All Phase N/A
V Valerie ROUILLE

Prospective Cohort With Hemopathy in Languedoc-Roussillon

Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.

18 years of age All Phase N/A
R Ross Soo, MD

Observational Study of Afatinib 30 mg Daily

Afatinib, a first-in-class irreversible ErbB family blocker, is a 1st line treatment option for patients with advanced stage NSCLC harbouring sensitizing EGFR mutations. In randomized 1st line studies of afatinib at a standard dose of 40 mg daily versus standard of care, 28-53% of patients required a dose reduction due …

18 - 99 years of age All Phase N/A

Simplify language using AI